TERN vs. INZY, AQST, ENTA, ENZ, NXTC, MORF, AVDL, SUPN, DVAX, and GMTX
Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Inozyme Pharma (INZY), Aquestive Therapeutics (AQST), Enanta Pharmaceuticals (ENTA), Enzo Biochem (ENZ), NextCure (NXTC), Morphic (MORF), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Dynavax Technologies (DVAX), and Gemini Therapeutics (GMTX). These companies are all part of the "medical" sector.
Terns Pharmaceuticals (NASDAQ:TERN) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
In the previous week, Inozyme Pharma had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for Inozyme Pharma and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.41 beat Inozyme Pharma's score of 1.19 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.
Terns Pharmaceuticals' return on equity of -35.54% beat Inozyme Pharma's return on equity.
Terns Pharmaceuticals has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
Terns Pharmaceuticals and Inozyme Pharma both received 35 outperform votes by MarketBeat users. However, 81.40% of users gave Inozyme Pharma an outperform vote while only 58.33% of users gave Terns Pharmaceuticals an outperform vote.
Inozyme Pharma has lower revenue, but higher earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Terns Pharmaceuticals currently has a consensus target price of $14.94, suggesting a potential upside of 136.35%. Inozyme Pharma has a consensus target price of $17.00, suggesting a potential upside of 286.36%. Given Inozyme Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Inozyme Pharma is more favorable than Terns Pharmaceuticals.
Summary
Terns Pharmaceuticals beats Inozyme Pharma on 8 of the 15 factors compared between the two stocks.
Get Terns Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Terns Pharmaceuticals Competitors List
Related Companies and Tools
